Ono Pharma's ONO-1110 misses primary endpoints in three Phase 2 pain studies
Bitget2026/10/29 03:03- Ono Pharmaceutical today announced plans for further ONO-1110 studies in postherpetic neuralgia, fibromyalgia and Hunner-type interstitial cystitis following pain-improvement signals.
- All three Phase 2 trials missed their primary endpoints; subgroup and exploratory analyses suggested pain relief.
- No further studies are planned in major depressive disorder or social anxiety disorder, where trials showed no efficacy signals.
- ONO-1110 demonstrated a favorable safety profile across all five studies.
- Detailed results will be presented at future conferences and through other appropriate channels.
Disclaimer: The content of this article solely reflects the author's opinion and does not represent the platform in any capacity. This article is not intended to serve as a reference for making investment decisions.
You may also like
Barclays: Bloom Energy (BE.US) demand turning point is steeper than expected, rating raised to "Buy"
Barclays has upgraded Bloom Energy’s rating from "equal weight" to "overweight," setting a target price of $289.
Competitor turns supplier as the "new owner"! Bank of America: Marvell Technology's acquisition of Lumentum may prompt Cisco and Ciena to seek other sources
Bank of America analysts stated that Marvell Technology's acquisition of Lumentum may prompt Ciena and Cisco to diversify their optical component suppliers.
Goldman Sachs traders warn of an "invisible bear market": S&P 500 is only 3% away from its all-time high, but 60% of its constituent stocks have entered bear market territory.
The S&P 500 Index is only about 3% away from its latest record high, but 60% of the constituent stocks in this benchmark index are deeply entrenched in bear market territory.
Crypto prices
More
